Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹337 Cr
up ₹15.3 Cr vs Jun 2016
- Stocks held
- 26
- unchanged
- Top 10 weight
- 74.7%
- of the portfolio in its ten largest
- Cash & debt
- 4.7%
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In July 2016 it disclosed 26 stocks worth ₹337 Cr, up ₹15.3 Cr from Jun 2016. Its largest positions were Sun Pharmaceutical Industries Limited (23.9%), Dr. Reddy's Laboratories Limited (10.2%), Lupin Limited (10.0%); the ten largest together made up 74.7% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 86.6% of its equity. Cash and debt stood at 4.7%. Compared with Jun 2016 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
95%
Top-10 weight is higher than 95% of peers
Breadth
10%
Holds more stocks than 10% of peers
Cash
67%
Holds more cash than 67% of peers
What these mean: concentration · cash
Holdings in July 2016
Download CSVEvery line the fund disclosed, with the change against Jun 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 23.85% | up 3.40 pts | ₹80.4 Cr | up ₹14.6 Cr | Added |
| Dr. Reddy's Laboratories Limited | 10.16% | down 2.10 pts | ₹34.3 Cr | down ₹5.2 Cr | Trimmed |
| Lupin Limited | 10.03% | up 0.73 pts | ₹33.8 Cr | up ₹3.9 Cr | Added |
| Cipla Limited | 8.48% | up 0.04 pts | ₹28.6 Cr | up ₹1.4 Cr | Added |
| Cash, TREPS & receivables | 4.68% | down 2.20 pts | ₹15.8 Cr | down ₹6.4 Cr | Trimmed |
| Divi's Laboratories Limited | 4.61% | up 0.14 pts | ₹15.5 Cr | up ₹1.2 Cr | Added |
| Biocon Limited | 4.47% | up 0.28 pts | ₹15.1 Cr | up ₹1.6 Cr | Added |
| Aurobindo Pharma Limited | 3.56% | up 0.06 pts | ₹12 Cr | up ₹74 L | Added |
| Piramal Enterprises Limited | 3.53% | down 0.39 pts | ₹11.9 Cr | down ₹70 L | Trimmed |
| Alkem Laboratories Limited | 3.42% | up 0.25 pts | ₹11.5 Cr | up ₹1.3 Cr | Added |
| Sun Pharma Advanced Research Company Limited | 2.58% | up 0.06 pts | ₹8.7 Cr | up ₹59 L | Added |
| Zydus Lifesciences Limited | 2.34% | up 0.15 pts | ₹7.9 Cr | up ₹83 L | Added |
| IPCA Laboratories Limited | 2.24% | up 0.02 pts | ₹7.5 Cr | up ₹40 L | Added |
| Narayana Hrudayalaya Limited | 2.17% | down 0.28 pts | ₹7.3 Cr | down ₹57 L | Trimmed |
| Strides Pharma Science Limited | 1.91% | down 0.03 pts | ₹6.5 Cr | up ₹19 L | Added |
| Pfizer Limited | 1.72% | up 0.01 pts | ₹5.8 Cr | up ₹30 L | Added |
| Sanofi India Limited | 1.58% | down 0.03 pts | ₹5.3 Cr | up ₹14 L | Added |
| Syngene International Limited | 1.58% | down 0.01 pts | ₹5.3 Cr | up ₹20 L | Added |
| Unichem Laboratories Limited | 1.47% | down 0.08 pts | ₹5 Cr | down ₹2 L | Held |
| GlaxoSmithKline Pharmaceuticals Limited | 1.25% | down 0.13 pts | ₹4.2 Cr | down ₹22 L | Trimmed |
| Natco Pharma Limited | 1.14% | up 0.04 pts | ₹3.8 Cr | up ₹32 L | Added |
| Indraprastha Medical Corporation Limited | 1.00% | down 0.05 pts | ₹3.4 Cr | down ₹2 L | Trimmed |
| Torrent Pharmaceuticals Limited | 0.61% | up <0.01 pts | ₹2.1 Cr | up ₹10 L | Added |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.56% | up 0.04 pts | ₹1.9 Cr | up ₹21 L | Added |
| Shilpa Medicare Limited | 0.52% | up 0.06 pts | ₹1.7 Cr | up ₹26 L | Added |
| Indoco Remedies Limited | 0.41% | up 0.02 pts | ₹1.4 Cr | up ₹14 L | Added |
| Thyrocare Technologies Limited | 0.12% | down 0.01 pts | ₹41 L | up ₹0 L | Held |
What changed, Jun 2016 to Jul 2016
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Sun Pharmaceutical Industries Limitedup ₹14.6 Cr (+3.40% pts)
- Lupin Limitedup ₹3.9 Cr (+0.73% pts)
- Biocon Limitedup ₹1.6 Cr (+0.28% pts)
- Cipla Limitedup ₹1.4 Cr (+0.04% pts)
- Alkem Laboratories Limitedup ₹1.3 Cr (+0.25% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jun 2016, the weight rose most in Pharmaceuticals & Biotechnology (+1.2 pts), and fell most in Finance (−0.5 pts) and Healthcare Services (−0.5 pts).
- Pharmaceuticals & Biotechnology85.5% → 86.6%+1.2 pts
- Finance4.2% → 3.7%−0.5 pts
- Healthcare Services5.6% → 5.1%−0.5 pts
- Pharmaceuticals4.7% → 4.6%−0.2 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jul 2015 | Jan 2016 | Apr 2016 | Jun 2016 | Jul 2016 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 92.7% | 86.7% | 86.7% | 85.5% | 86.6% |
| Healthcare Services | — | 5.5% | 5.1% | 5.6% | 5.1% |
| Pharmaceuticals | 6.3% | 4.8% | 4.7% | 4.7% | 4.6% |
| Finance | 1.0% | 3.0% | 3.6% | 4.2% | 3.7% |
Allocation in Jul 2016change vs Jun 2016
- Pharmaceuticals & Biotechnology (17)86.6%▲ 1.2 pts
- Healthcare Services (4)5.1%▼ 0.5 pts
- Pharmaceuticals (4)4.6%▼ 0.2 pts
- Finance (1)3.7%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Jul 2016
4.7%
▼ 2.2 pts vs Jun 2016
- Cash alone
- 4.7%
- cash and net receivables
- A year earlier
- 9.5%
- Jul 2015 · now ▼ 4.8 pts
- Last 12 months
- 4.7% – 12.6%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.